title: Carbapenem resistance in Acinetobacter baumannii: where is it heading?
abstract: In the context of the substantial increase in antibiotic resistance rates of Acinetobacter baumannii, we aimed to evaluate the susceptibility rate changes of A. baumannii strains for carbapenems. A. baumannii strains isolated from patients diagnosed with healthcare-associated infections between 2007-2010 were included. A total of 127 A. baumannii strains [53 (42%) from the intensive care unit and 74 (58%) from the non-intensive care unit] were isolated. Conventional methods and an automated microbiology system were used for identification. Susceptibility testing was studied by Kirby-Bauer disk diffusion method. In 2007, five of 26 strains, in 2008, 18 of 31, in 2009, 10 of 35, in 2010, and 20 of 35 were obtained from intensive care unit patients. The susceptibility rate for imipenem was 50% in 2007 but 20% in 2010, while for meropenem it was 55% in 2007 but 12% in 2010. Prevention and control of antibiotic resistance among Acinetobacter species needs antibiotic usage restrictions and infection control precautions.
authors.affiliation: Department of Infectious Diseases and Clinical Microbiology; Department of Microbiology and Clinical Microbiology, Dicle University, Faculty of Medicine, Diyarbak?r, Turkey.
authors.forename: Özcam
authors.initials: Ö
authors.lastname: Deveci
authors.forename: Tuba
authors.initials: T
authors.lastname: Dal
authors.forename: Recep
authors.initials: R
authors.lastname: Tekin
authors.forename: Fatma
authors.initials: F
authors.lastname: Bozkurt
authors.forename: Alicem
authors.initials: A
authors.lastname: Tekin
authors.forename: Saim
authors.initials: S
authors.lastname: Dayan
mesh_terms: D000151:Acinetobacter Infections / Q000453:epidemiology / Q000382:microbiology; D040981:Acinetobacter baumannii / Q000187:drug effects / Q000302:isolation & purification; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015780:Carbapenems / Q000494:pharmacology*; D003428:Cross Infection / Q000453:epidemiology / Q000382:microbiology; D006785:Hospitals, University; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D007362:Intensive Care Units; D000077731:Meropenem; D008826:Microbial Sensitivity Tests / Q000379:methods; D011379:Prognosis; D012307:Risk Factors; D013845:Thienamycins / Q000494:pharmacology; D014421:Turkey / Q000453:epidemiology; D018440:beta-Lactam Resistance
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D013845:Thienamycins; D015378:Imipenem; D000077731:Meropenem